Halnac-AQ Injection contains Diclofenac 75 mg/ml, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of acute pain and inflammation associated with musculoskeletal disorders, postoperative pain, and other inflammatory conditions. Diclofenac exerts its therapeutic effects by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins, which are mediators of inflammation and pain. Halnac-AQ Injection is administered via intramuscular or intravenous routes, providing rapid onset of analgesic and anti-inflammatory action. It is particularly useful in patients requiring prompt relief from moderate to severe pain where oral administration is not feasible. The dosage and duration of treatment should be individualized based on the severity of symptoms and patient response, with caution advised in patients with a history of gastrointestinal disorders, cardiovascular disease, renal or hepatic impairment. Common adverse effects may include gastrointestinal discomfort, injection site reactions, and transient elevations in liver enzymes. Use of Halnac-AQ Injection is contraindicated in patients with known hypersensitivity to diclofenac or other NSAIDs, active peptic ulceration, and severe heart failure. Monitoring for adverse effects and appropriate patient selection are essential to optimize therapeutic outcomes while minimizing risks.